The severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2) pandemic is a
significant global issue that has major implications for the healthcare system. The mortality …

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …

Among the IL-6 inhibitors, tocilizumab is the most widely used therapeutic option in patients
with SARS-CoV-2-associated severe respiratory failure (SRF). The aim of our study was to …

Background: The optimal approach for adult patients hospitalized with severe and critical
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm …

近年来, 肿瘤免疫疗法取得了显著的临床疗效, 但部分患者会产生免疫介导毒性,
其中最常见的是细胞因子释放综合征(cytokine release syndrome, CRS). CRS …

Abstract Introduction Despite Tocilizumab is now recognized as a concrete therapeutic
option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about …

OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19)
demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical …

Allogeneic hematopoietic stem cell transplantation (HSCT) and coronavirus disease 2019
(COVID-19) infection can both lead to severe cytokine release syndrome (sCRS) resulting in …

Purpose: The IL-6 receptor inhibitor tocilizumab reduces mortality and morbidity in severe
cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant …